CO2022018192A2 - Potentes anticuerpos neutralizantes contra el sars-cov-2, generación y usos de los mismos - Google Patents

Potentes anticuerpos neutralizantes contra el sars-cov-2, generación y usos de los mismos

Info

Publication number
CO2022018192A2
CO2022018192A2 CONC2022/0018192A CO2022018192A CO2022018192A2 CO 2022018192 A2 CO2022018192 A2 CO 2022018192A2 CO 2022018192 A CO2022018192 A CO 2022018192A CO 2022018192 A2 CO2022018192 A2 CO 2022018192A2
Authority
CO
Colombia
Prior art keywords
cov
generation
antibodies against
neutralizing antibodies
against sars
Prior art date
Application number
CONC2022/0018192A
Other languages
English (en)
Spanish (es)
Inventor
David D Ho
Yaoxing Huang
Lihong Liu
Yang Luo
Manoj S Nair
Pengfei Wang
Jian Yu
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia filed Critical Univ Columbia
Publication of CO2022018192A2 publication Critical patent/CO2022018192A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CONC2022/0018192A 2020-05-20 2022-12-15 Potentes anticuerpos neutralizantes contra el sars-cov-2, generación y usos de los mismos CO2022018192A2 (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063027935P 2020-05-20 2020-05-20
US202063032518P 2020-05-29 2020-05-29
US202063039977P 2020-06-16 2020-06-16
US202063060116P 2020-08-02 2020-08-02
US202063063106P 2020-08-07 2020-08-07
US202063117908P 2020-11-24 2020-11-24
US202063123767P 2020-12-10 2020-12-10
US202163165729P 2021-03-24 2021-03-24
PCT/US2021/033512 WO2021236997A2 (en) 2020-05-20 2021-05-20 Potent neutralizing antibodies against sars-cov-2, generation and uses thereof

Publications (1)

Publication Number Publication Date
CO2022018192A2 true CO2022018192A2 (es) 2023-03-17

Family

ID=78707603

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0018192A CO2022018192A2 (es) 2020-05-20 2022-12-15 Potentes anticuerpos neutralizantes contra el sars-cov-2, generación y usos de los mismos

Country Status (13)

Country Link
US (3) US20240002476A1 (enExample)
EP (1) EP4153625A4 (enExample)
JP (1) JP2023526469A (enExample)
KR (1) KR20230024904A (enExample)
AU (1) AU2021277373A1 (enExample)
BR (1) BR112022023467A2 (enExample)
CA (1) CA3184184A1 (enExample)
CL (1) CL2022003215A1 (enExample)
CO (1) CO2022018192A2 (enExample)
IL (1) IL298263A (enExample)
MX (1) MX2022014420A (enExample)
PH (1) PH12022500025A1 (enExample)
WO (4) WO2021236997A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021195418A1 (en) 2020-03-26 2021-09-30 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
CA3184184A1 (en) * 2020-05-20 2021-11-25 The Trustees Of Columbia University In The City Of New York Potent neutralizing antibodies against sars-cov-2, generation and uses thereof
WO2024089277A2 (en) * 2022-10-27 2024-05-02 Oxford University Innovation Limited Antibodies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070052273A (ko) * 2004-06-30 2007-05-21 아이디 바이오메디컬 코포레이션 오브 퀘벡 코로나바이러스 감염의 치료를 위한 백신 조성물
WO2006124269A2 (en) * 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
CN101627055A (zh) * 2006-09-05 2010-01-13 梅达雷克斯公司 骨形成蛋白及其受体的抗体以及它们的使用方法
US7982016B2 (en) * 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
WO2009128963A2 (en) * 2008-01-17 2009-10-22 Humab, Llc Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
WO2010043977A2 (en) * 2008-10-13 2010-04-22 Institute For Research In Biomedicine Dengue virus neutralizing antibodies and uses thereof
US9221902B2 (en) * 2008-11-07 2015-12-29 Fabrus, Inc. Combinatorial antibody libraries and uses thereof
EP3077051B1 (en) * 2013-12-02 2023-04-12 The Trustees of Columbia University in the City of New York Improved hiv-1-neutralizing antibody potency and breadth via cell receptor anchoring using bispecific antibodies with native architecture
US10301377B2 (en) * 2015-02-24 2019-05-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
HK1253507A1 (zh) * 2015-05-18 2019-06-21 Eureka Therapeutics, Inc. 抗 ror1 抗体
AU2016332900C1 (en) * 2015-09-29 2024-07-04 Amgen Inc. ASGR inhibitors
CR20180365A (es) * 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
TWI848953B (zh) * 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
MY201995A (en) * 2018-07-09 2024-03-28 Five Prime Therapeutics Inc Antibodies binding to ilt4
CA3184184A1 (en) * 2020-05-20 2021-11-25 The Trustees Of Columbia University In The City Of New York Potent neutralizing antibodies against sars-cov-2, generation and uses thereof

Also Published As

Publication number Publication date
WO2021236995A2 (en) 2021-11-25
JP2023526469A (ja) 2023-06-21
WO2021236997A3 (en) 2022-09-29
WO2021236995A3 (en) 2022-09-15
CL2022003215A1 (es) 2023-07-07
US20230203138A1 (en) 2023-06-29
WO2021236998A3 (en) 2021-12-16
WO2021236996A2 (en) 2021-11-25
MX2022014420A (es) 2023-03-21
PH12022500025A1 (en) 2024-03-25
WO2021236998A2 (en) 2021-11-25
AU2021277373A1 (en) 2023-01-05
CA3184184A1 (en) 2021-11-25
US20240002476A1 (en) 2024-01-04
WO2021236997A2 (en) 2021-11-25
US20230203134A1 (en) 2023-06-29
BR112022023467A2 (pt) 2023-03-28
WO2021236998A9 (en) 2022-03-31
IL298263A (en) 2023-01-01
EP4153625A4 (en) 2024-09-25
KR20230024904A (ko) 2023-02-21
WO2021236996A3 (en) 2022-11-17
EP4153625A2 (en) 2023-03-29

Similar Documents

Publication Publication Date Title
CL2019002792A1 (es) Composición para producir tagatosa y procedimiento de producción de tagatosa usando el mismo.
AR125562A2 (es) Aparato y método para la para la generación de una descripción de una escena de audio combinada
SV2017005582A (es) Sistema y metodo para el crecimiento y el procesamiento de biomasa
AR123061A1 (es) Generación de información de información relacionada con la integridad para el posicionamiento
AR105433A1 (es) Métodos para mejorar la eficacia y expansión de las células inmunes
DK1623017T3 (da) Frembringelse og isolering af antigenspecifikke T-celler
CL2022003215A1 (es) Anticuerpos neutralizantes potentes contra la sars-cov-2, su generación y usos.
MX2021013631A (es) Anticuerpos anti-cd40 para el uso en el tratamiento de t1dm e insulitis.
NI202000087A (es) Anticuerpos ant-tmeff2 monoespecíficos y multiespecíficos y sus usos
CR20230525A (es) Anticuerpos anti-cd20 y estructuras car-t
PH12019502475A1 (en) Transmitting method for synchronization signal, receiving method for synchronization signal, and related devices
BR102018074536A8 (pt) Reforma estrutural de painéis de núcleo celular
MX2020004869A (es) Metodo para preparar derivado de benzofurano.
MX2022012740A (es) Composicion de fragancia.
MX2018014554A (es) Anticuerpo penetrante de citosol y uso del mismo.
CO2020013533A2 (es) Sistemas, métodos y composición de uso de mutantes de rnasa iii para producir sarn para controlar infección por patógeno huésped
EA201591934A1 (ru) Плазменная перфорация
AR121129A1 (es) Anticuerpos anti-e-selectina, composiciones y métodos de uso
JP1774471S (ja) 発電機
JP1774472S (ja) 発電機
JP1774469S (ja) 発電機
JP1774470S (ja) 発電機
JP1810140S (ja) 核融合エネルギー生成装置用ユニット
UY37467A (es) Método para crear un compuesto a base de mercurio, compuesto a base de mercurio, métodos de uso del compuesto a base de mercurio y usos del compuesto a base de mercurio
AR116538A1 (es) Fructosa-4-epimerasa y método de producción de tagatosa mediante su uso